Skip to content

Anticoagulation Medical Home

Anticoagulation Medical Home for High-Risk Patients With Venous Thromboembolism: Patient Education, Anticoagulant Decision-Making, and Patient Self-Efficacy in the Home Coordinated by the UMass Anticoagulation Team

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02870296
Enrollment
162
Registered
2016-08-17
Start date
2016-10-21
Completion date
2018-01-05
Last updated
2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient-Centered Care, Venous Thromboembolism

Brief summary

The primary study goal is to improve the quality of care transitions for patients with new episodes of venous thromboembolism (VTE). Primary Outcomes: To measure differences in the quality of care transition, as measured by the Care Transition Measure (CTM)-15 in the investigators target population of patients with incident VTE randomized to either a multicomponent, anticoagulation medical home intervention or usual care. Secondary Major Outcomes: To measure the difference in recurrent VTE, major hemorrhage, all-cause re-admissions, and mortality between the investigators intervention and comparison groups at 30 and 90 days in the investigators target population. Secondary Other Outcomes: To measure patient knowledge, health-related quality of life, and time in the therapeutic range (TTR) for patients on warfarin in the investigators target population.

Interventions

BEHAVIORALEnhanced Assessment and Education

Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).

Sponsors

Pfizer
CollaboratorINDUSTRY
University of Massachusetts, Worcester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* hospital admission; * diagnosis of: * VTE (first or subsequent episode); or * DVT of leg or pelvis or upper extremities or other site confirmed by ultrasound or CT scan; or * PE with a positive CT spiral exam, pulmonary arteriogram, CT angiogram, or high probability ventilation perfusion scan. * for whom it is anticipated the treating medical team will prescribe an oral anticoagulant upon hospital discharge.

Exclusion criteria

* Not engaged in Primary Care (has not seen a Primary Care Practitioner within the previous 18 months).

Design outcomes

Primary

MeasureTime frameDescription
Care Transition Measure (CTM-15)30 days post hospital discharge15 item measure; measures 4 aspects of quality of transitional care

Secondary

MeasureTime frameDescription
Clinical Outcome: VTE Recurrence30 and 90 days post hospital dischargeMeasure the difference in recurrent VTE between intervention and comparison groups.
Clinical Outcome: Major Hemorrhage (noted in Medical Record and/or via patient self-report)30 and 90 days post hospital dischargeMeasure the difference in major hemorrhage between intervention and comparison groups- ISTH 2005 medical definition 14 - 2 unit drop in hemoglobin, 2 unit transfusion, or critical site bleed. \- ISTH 2009 surgical definition 15 - surgical site 2 unit drop or 2 unit transfusion with increase in LOS, hemodynamic compromise, delay in rehab.
Other Measure: Patient Knowledge (via questionnaire developed by Mazor et. al. 2007 Patient Educ Counsel and via investigator developed items)30 and 90 days post hospital dischargeMeasure patient knowledge and attitudes Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns. 2007 Dec;69(1-3):145-57. Epub 2007 Oct 17.
Clinical Outcome: Mortality30 and 90 days post hospital dischargeMeasure the difference in mortality between intervention and comparison groups.
Other Measure: Quality of Life (VEINES-QOL/Sym questionnaire or PEmb-QoL questionnaire)30 and 90 days post hospital dischargeMeasure health-related quality of life for patients on warfarin and time in the therapeutic range (TTR) in our target population
Clinical Outcome: Hospital Readmission (any unplanned hospital admissions noted in Medical Record and/or via patient self-report)30 and 90 days post hospital dischargeMeasure the difference between all cause hospital readmission (post-diagnosis of VTE) between intervention and comparison groups.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026